1.
The effect of L-arginine supplementation on maximal oxygen uptake: A systematic review and meta-analysis.
Rezaei, S, Gholamalizadeh, M, Tabrizi, R, Nowrouzi-Sohrabi, P, Rastgoo, S, Doaei, S
Physiological reports. 2021;(3):e14739
Abstract
BACKGROUND The efficacy and safety of L-arginine supplements and their effect on maximal oxygen uptake (VO2 max) remained unclear. This systematic review aimed to investigate the effect of L-arginine supplementation (LAS) on VO2 max in healthy people. METHODS We searched PubMed, Scopus, Web of Science, Cochrane, Embase, ProQuest, and Ovid to identify all relevant literature investigating the effect of LAS on VO2 max. This meta-analysis was conducted via a random-effects model for the best estimation of desired outcomes and studies that meet the inclusion criteria were considered for the final analysis. RESULTS The results of 11 randomized clinical trials indicated that LAS increased VO2 max compared to the control group. There was no significant heterogeneity in this meta-analysis. Subgroup analysis detected that arginine in the form of LAS significantly increased VO2 max compared to the other forms (weighted mean difference = 0.11 L min-1 , I2 = 0.0%, p for heterogeneity = 0.485). CONCLUSIONS This meta-analysis indicated that supplementation with L-arginine could increase VO2 max in healthy people. Further studies are warranted to confirm this finding and to identify the underlying mechanisms.
2.
Meta-analysis of Oxygenation Saturation Targeting Trials: Do Infant Subgroups Matter?
Askie, LM
Clinics in perinatology. 2019;(3):579-591
Abstract
Participant data from approximately 5000 infants have been meta-analyzed to guide oxygen saturation policy for extremely preterm infants. The Neonatal Oxygenation Prospective Meta-analysis showed that targeting a higher oxygen saturation range compared with a lower range resulted in decreased death and necrotizing enterocolitis and no difference in major disability but increased treated retinopathy of prematurity (ROP) and supplemental oxygen use at 36 weeks' postmenstrual age. The 91% to 95% range can be recommended for all extremely preterm infants from birth but should be accompanied by stringent surveillance for the prevention and early treatment of ROP.